Compare SRRK & MSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | MSM |
|---|---|---|
| Founded | 2012 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 2018 | 1996 |
| Metric | SRRK | MSM |
|---|---|---|
| Price | $42.97 | $89.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $55.40 | ★ $91.00 |
| AVG Volume (30 Days) | ★ 1.5M | 550.5K |
| Earning Date | 03-03-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 3.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | N/A | ★ $3,363,817,000.00 |
| Revenue This Year | N/A | $5.88 |
| Revenue Next Year | $550.26 | $5.16 |
| P/E Ratio | ★ N/A | $96.73 |
| Revenue Growth | N/A | ★ 4.99 |
| 52 Week Low | $22.71 | $68.10 |
| 52 Week High | $49.82 | $96.99 |
| Indicator | SRRK | MSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 48.81 |
| Support Level | $41.07 | $87.44 |
| Resistance Level | $48.23 | $93.83 |
| Average True Range (ATR) | 2.43 | 2.98 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 45.94 | 51.58 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.